Recent cases involve charges and judgments related to COVID-19 add-on tests, genetic testing fraud, and kickbacks.
Our upcoming event will provide lab leaders with analysis of recent legal and regulatory developments, enforcement trends, and more
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
False billing of urine drug tests (UDTs) continues to be a focus for enforcement agencies in 2023, here’s how to avoid compliance issues.
Though UDT-related enforcement actions predominate, an uncommon vendor-related case was in the mix this month.